tiprankstipranks
Trending News
More News >
Jubilant Ingrevia Ltd. (IN:JUBLINGREA)
:JUBLINGREA
India Market
Advertisement

Jubilant Ingrevia Ltd. (JUBLINGREA) AI Stock Analysis

Compare
1 Followers

Top Page

IN:JUBLINGREA

Jubilant Ingrevia Ltd.

(JUBLINGREA)

Select Model
Select Model
Select Model
Neutral 63 (OpenAI - 4o)
Rating:63Neutral
Price Target:
₹722.00
▲(3.24% Upside)
Jubilant Ingrevia Ltd. demonstrates strong financial performance with stable margins and profitability, which is the most significant factor in its overall score. However, technical analysis indicates a bearish trend, and the valuation suggests the stock is relatively expensive, both of which weigh down the overall score.

Jubilant Ingrevia Ltd. (JUBLINGREA) vs. iShares MSCI India ETF (INDA)

Jubilant Ingrevia Ltd. Business Overview & Revenue Model

Company DescriptionJubilant Ingrevia Ltd. (JUBLINGREA) is a leading manufacturer and supplier of specialty chemicals and life science ingredients, operating primarily in the pharmaceutical, agriculture, and food sectors. The company focuses on providing innovative and high-quality products, including intermediates, active pharmaceutical ingredients (APIs), and excipients. With a strong emphasis on sustainability and research and development, Jubilant Ingrevia is committed to delivering value through its diverse portfolio and extensive market reach.
How the Company Makes MoneyJubilant Ingrevia generates revenue through several key streams, primarily by producing and selling specialty chemicals and life science ingredients. The company earns significant income from its pharmaceutical segment, where it supplies APIs and intermediates to major global pharmaceutical companies. Additionally, it derives revenue from its agriculture segment by providing crop protection chemicals and agrochemical products. The food segment contributes to earnings through the sale of food additives and ingredients. Strategic partnerships with leading firms in various industries enhance its market position and contribute to stable revenue growth. The company also invests in R&D to innovate and expand its product offerings, which can lead to increased sales and market share.

Jubilant Ingrevia Ltd. Financial Statement Overview

Summary
Jubilant Ingrevia Ltd. shows strong financial health with consistent revenue and profit growth, stable margins, and a solid equity foundation. While there are fluctuations in revenue and cash flow management, the company's operational efficiency and profitability are strong. Attention to leverage and cash flow generation is crucial for sustained growth.
Income Statement
75
Positive
The income statement shows a consistent growth trajectory in revenue over the years, with a noticeable increase in gross and net profit margins. However, there was a dip in revenue in 2024, followed by recovery in 2025. The EBIT and EBITDA margins have been stable, indicating efficient operations. Overall, the company demonstrates a strong ability to generate profits, though fluctuations in revenue growth present moderate risk.
Balance Sheet
68
Positive
The balance sheet reveals a solid equity position with a reasonable debt-to-equity ratio indicating moderate leverage. Return on equity has been healthy, supporting profitability. However, increasing total liabilities highlight potential risk if revenue does not continue to grow. The equity ratio is strong, suggesting good financial stability.
Cash Flow
70
Positive
The company's cash flow statement shows robust operating cash flow and a positive free cash flow trend in the latest year. The operating cash flow to net income ratio indicates strong cash generation relative to profits. However, previous periods showed negative free cash flow, pointing to potential challenges in managing capital expenditures effectively.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue41.59B41.78B41.36B47.73B49.49B6.83B
Gross Profit17.81B16.07B18.98B20.44B19.56B1.37B
EBITDA5.91B5.57B4.56B5.81B8.63B1.07B
Net Income2.78B2.51B1.83B3.08B4.77B543.59M
Balance Sheet
Total Assets0.0050.32B47.32B42.59B37.97B33.79B
Cash, Cash Equivalents and Short-Term Investments1.15B1.15B828.36M1.08B454.69M1.17B
Total Debt0.007.64B7.40B4.07B2.38B5.56B
Total Liabilities-29.27B21.05B19.94B15.93B13.64B14.56B
Stockholders Equity29.27B29.27B27.37B26.66B24.33B19.23B
Cash Flow
Free Cash Flow0.001.42B-1.38B-189.30M2.23B847.36M
Operating Cash Flow0.005.08B4.30B4.62B4.53B1.12B
Investing Cash Flow0.00-3.93B-5.70B-4.72B-718.56M-436.55M
Financing Cash Flow0.00-1.29B1.44B416.00M-4.18B-723.65M

Jubilant Ingrevia Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price699.35
Price Trends
50DMA
693.80
Negative
100DMA
726.17
Negative
200DMA
702.88
Negative
Market Momentum
MACD
-0.43
Negative
RSI
51.86
Neutral
STOCH
39.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JUBLINGREA, the sentiment is Positive. The current price of 699.35 is above the 20-day moving average (MA) of 676.66, above the 50-day MA of 693.80, and below the 200-day MA of 702.88, indicating a neutral trend. The MACD of -0.43 indicates Negative momentum. The RSI at 51.86 is Neutral, neither overbought nor oversold. The STOCH value of 39.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:JUBLINGREA.

Jubilant Ingrevia Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
₹112.63B48.610.17%21.50%78.82%
₹134.81B60.190.09%34.62%126.53%
₹110.27B37.920.72%3.80%64.94%
₹98.23B52.620.53%10.29%26.09%
$10.43B7.12-0.05%2.87%2.86%-36.73%
₹124.21B79.960.07%69.32%113.55%
₹97.53B125.610.38%103.52%-42.97%
* Basic Materials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:JUBLINGREA
Jubilant Ingrevia Ltd.
690.00
-22.05
-3.10%
IN:ALKYLAMINE
Alkyl Amines Chemicals Limited
1,903.40
-174.48
-8.40%
IN:AMIORG
Ami Organics Ltd.
1,689.90
702.48
71.14%
IN:ANURAS
Anupam Rasayan India Ltd.
1,089.15
354.38
48.23%
IN:PRIVISCL
Privi Speciality Chemicals Limited
2,860.15
1,136.25
65.91%
IN:SUDARSCHEM
Sudarshan Chemical Industries Limited
1,182.55
139.19
13.34%

Jubilant Ingrevia Ltd. Corporate Events

Jubilant Ingrevia Successfully Concludes 6th AGM with All Resolutions Passed
Aug 29, 2025

Jubilant Ingrevia Limited held its 6th Annual General Meeting on August 29, 2025, via video conferencing, where all resolutions were passed with the required majority. The company submitted the scrutinizer’s report and voting results to the exchange, complying with SEBI regulations. The documents are available on the company’s website and the National Securities Depositories Limited platform.

Jubilant Ingrevia Successfully Concludes 6th AGM with All Resolutions Passed
Aug 29, 2025

Jubilant Ingrevia Limited held its 6th Annual General Meeting on August 29, 2025, where all proposed resolutions were passed with the required majority. The meeting was conducted via video conferencing, and the results, along with other relevant documents, have been made available on the company’s website. This successful AGM indicates strong shareholder support for the company’s current strategies and governance, potentially reinforcing its market position and stakeholder confidence.

Jubilant Ingrevia Announces Key Leadership Appointments at AGM
Aug 29, 2025

Jubilant Ingrevia Limited held its 6th Annual General Meeting on August 29, 2025, where several key appointments and re-appointments were made, including directors and auditors. These changes are significant for the company’s governance and strategic direction, ensuring continuity and expertise in its leadership team, which is crucial for maintaining its competitive position in the industry.

Jubilant Ingrevia to Engage with Key Institutional Investors at Equirus Conference
Aug 12, 2025

Jubilant Ingrevia Limited has announced that its management will meet with various institutional investors at the Equirus Annual India Conference 2025 in Mumbai. This engagement with prominent investors and asset managers is part of the company’s efforts to strengthen its investor relations and potentially enhance its market positioning.

Jubilant Ingrevia’s Commercial Papers Retain High Credit Rating
Aug 12, 2025

Jubilant Ingrevia Limited has announced that CRISIL Ratings Limited has reaffirmed its ‘Crisil A1+’ rating on the company’s Rs. 600 crore Commercial Papers. This reaffirmation of the high credit rating underscores the company’s strong financial position and stability, which is likely to bolster stakeholder confidence and enhance its market reputation.

Jubilant Ingrevia Announces Record Date for Commercial Paper Maturity
Aug 12, 2025

Jubilant Ingrevia Limited has announced the record date for the maturity of its commercial papers, which is set for September 24, 2025. The commercial papers, issued on August 11, 2025, with an issue size of Rs. 50 Crore, will mature on September 25, 2025, and are listed on the National Stock Exchange of India Limited. This announcement is crucial for stakeholders to track financial obligations and manage investments effectively.

Jubilant Ingrevia Announces 6th AGM with Enhanced Digital Accessibility
Aug 5, 2025

Jubilant Ingrevia Limited has announced its 6th Annual General Meeting (AGM) scheduled for August 29, 2025. The company has provided the AGM notice and the Annual Report for the financial year 2024-25 to its members, ensuring accessibility through electronic means and physical dispatch for those without registered email addresses. The AGM will be conducted via video conferencing, and shareholders have been given the option to vote electronically both before and during the meeting. This announcement underscores Jubilant Ingrevia’s commitment to maintaining transparent communication with its stakeholders and adapting to digital platforms for corporate governance activities.

Jubilant Ingrevia to Host 6th AGM Virtually, Distributes Annual Reports Electronically
Aug 5, 2025

Jubilant Ingrevia Limited has announced its 6th Annual General Meeting (AGM) scheduled for August 29, 2025, which will be conducted via video conferencing. The company is ensuring compliance with regulatory requirements by distributing electronic copies of the AGM notice and the annual report for the financial year 2024-25 to registered members. This move reflects the company’s commitment to maintaining transparent communication with its stakeholders and adapting to digital platforms for efficient operations.

Jubilant Ingrevia Announces Virtual AGM and Annual Report Release
Aug 3, 2025

Jubilant Ingrevia Limited has announced that its 6th Annual General Meeting (AGM) will be held on August 29, 2025, via video conferencing. The company has published newspaper advertisements in Financial Express and Jansatta to inform shareholders about the AGM and the availability of the annual report for the financial year 2024-25, which will be sent electronically to registered shareholders.

Jubilant Ingrevia Engages with Global Investors at Nuvama India Conference
Aug 1, 2025

Jubilant Ingrevia Ltd. has announced its participation in the Nuvama India Conference in Singapore, where its management will engage with various institutional investors through one-on-one and group meetings. This initiative is part of the company’s strategy to strengthen relationships with key stakeholders and enhance its visibility in the investment community.

Jubilant Ingrevia Releases Q1 FY26 Investors’ Call Recording
Jul 31, 2025

Jubilant Ingrevia Limited has announced that the audio recording of its investors’ conference call, discussing the unaudited financial results for the quarter ending June 30, 2025, is now available on the company’s website. This disclosure aligns with the company’s commitment to transparency and regulatory compliance, potentially enhancing investor confidence and engagement.

Jubilant Ingrevia Releases Investor Call Recording for Q1 FY26
Jul 31, 2025

Jubilant Ingrevia Limited has announced that the audio recording of its investors’ conference call, discussing the unaudited financial results for the quarter ending June 30, 2025, is now available on the company’s website. This disclosure is in compliance with Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, ensuring transparency and accessibility for stakeholders.

Jubilant Ingrevia Fulfills Rs. 100 Crore Commercial Paper Obligation
Jul 31, 2025

Jubilant Ingrevia Limited, a company involved in the chemical industry, has announced that it has successfully fulfilled its financial obligation by redeeming a Commercial Paper worth Rs. 100 Crores. This update signifies the company’s commitment to maintaining its financial health and reliability in the market, potentially strengthening its position and trust among stakeholders.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 30, 2025